A meta-analysis of the relationship between lymphatic microvessel density and clinicopathological parameters in breast cancer

2013 ◽  
Vol 100 (3) ◽  
pp. E1-E10 ◽  
Author(s):  
Yigang Chen ◽  
Jun Yan ◽  
Ziming Yuan ◽  
Song Yu ◽  
Chengguang Yang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Microvessel Density ◽  
Meta Analysis ◽  
Clinicopathological Parameters ◽  
Lymphatic Microvessel Density ◽  
The Relationship

scholarly journals Prognostic and Clinicopathological Value of Slug Expression in Breast Cancer: A Meta-analysis

2021 ◽  
Author(s):  
Zhihao Zhang ◽  
Yueyuan Wang ◽  
Xiao Xie ◽  
Jingyu Peng ◽  
Xue Wei ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tumor Size ◽  
Histological Grade ◽  
Meta Analysis ◽  
Tnm Stage ◽  
Clinicopathological Parameters ◽  
Axillary Lymph ◽  
Slug Expression ◽  
Her 2 ◽  
The Relationship

Abstract 1.1 Background Slug as a member of the epithelial-mesenchymal transition(EMT) leads to the decrease of adhesion between cancer cells and the increase of cell migration. Many studies have been reported the relationship between prognosis and slug expression in patients with breast cancer, yet the results are controversial. Therefore, it is necessary to conclude the relationship between slug and breast cancer by a meta-analysis. 1.2 Methods We looked for studies on breast cancer and slug via PubMed, Scopus and Web of Science .A total of 1458 patients from the final eight studies were included in this meta-analysis. Overall survival (OS) and Disease-free survival (DFS) were the primary endpoints. Pooled hazard ratio (HR), pooled odds ratio (OR), and 95% confidence interval (CI) were calculated to assess the association between slug, prognosis, and clinicopathological parameters (age, tumor size, histological grade, axillary lymph nodes status(LN),TNM stage, ER(estrogen receptor) status, PR(progesterone receptor) status, HER-2(human epidermal growth factor receptor 2)status). Data analysis was carried out by using STATA version 14.0. (Stata Corporation, TX, USA)software. 1.3 Results This meta-analysis included 1458 patients from eight studies. The final results show that high slug expression leads to poor OS（pooled HR = 2.21;95%CI=1.47-3.33;p＜0.001) and DFS （pooled HR = 2.03;95%CI=1.26-3.28; P=0.004) in breast cancer. In terms of clinicopathological parameters, the results show that breast cancer patients with high slug expression have higher TNM stage(I-II/III-IV; pooled OR=0.42;95%CI=0.25-0.70;P=0.001), more prone to axillary lymph node metastasis(N+/N0;pooled OR =2.16; 95%CI =1.31-3.56; P=0.003) and more severe ER deficiency (positive /negative; pooled OR=0.67;95%CI=0.45-0.99; P=0.042).However, slug is not related to age, histological grade, tumor size, PR status and Her-2 status. 1.4 Conclusion This meta-analysis results show that high slug expression in breast cancer is associated with poor OS, DFS and axillary lymph node status, TNM stage and ER status, but not related to age, histological grade, tumor size, PR status and Her-2 status.

scholarly journals Association Between Long Non-Coding RNA POLR2E rs3787016 Polymorphism and Cancer Susceptibility: A Meta-analysis of 8725 Cancer Cases and 10710 Controls

2020 ◽  
Vol In Press (In Press) ◽  
Author(s):  
Saeid Ghavami ◽  
Mohsen Taheri ◽  
Mohammad Hashemi
Keyword(s):  
Breast Cancer ◽  
Web Of Science ◽  
Cancer Susceptibility ◽  
Meta Analysis ◽  
Positive Association ◽  
Cancer Development ◽  
Non Coding Rna ◽  
Stratified Analysis ◽  
The Relationship ◽  
Long Non Coding Rna

Objectives: Several studies have reported a correlation between the POLR2E rs3787016 polymorphism and cancer development, but findings are inconsistent. Therefore, we designed the current study to understand how rs3787016 polymorphism impacts cancer susceptibility. Methods: We searched the Scopus, Web of Science, and PubMed databases for studies related to the topic of interest published up to March 2019. A total of 11 relevant studies, encompassing 8,761 cancer cases and 10,534 controls, were retrieved and subject to quantitative analysis. The strength of the relationship was evaluated using the pooled odds ratios (ORs) with 95% confidence intervals (CIs). Results: Overall, the findings proposed a positive association between rs189037 polymorphism and susceptibility to cancer in homozygous (OR = 1.32, 95% CI = 1.11 - 1.57, P = 0.002, TT vs. CC), recessive (OR = 1.21, 95% CI = 1.06-1.39, P = 0.005, TT vs. CT + CC), and allele (OR = 1.12, 95% CI = 1.02-1.22, P = 0.021, T vs. C) genetic models. Stratified analysis showed that rs3787016 increased the risk of prostate and breast cancer. In addition, we found a significant association between the variant and increased cancer risk in Asian and Caucasian populations. Conclusions: In summary, the findings of the current meta-analysis suggest that the POLR2E rs3787016 polymorphism is an indicator of cancer susceptibility.

scholarly journals The Relationship between Telomerase Activity and Clinicopathological Parameters in Colorectal Cancer: A Meta-Analysis

2016 ◽  
Vol 33 (1) ◽  
pp. 64-71 ◽  
Author(s):  
Xue Cheng Xie ◽  
Lian Ying Ge ◽  
Hao Lai ◽  
Hai Qiu ◽  
Fan Tang ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Meta Analysis ◽  
Telomerase Activity ◽  
Clinicopathological Parameters ◽  
The Relationship

scholarly journals The relationship between dairy products intake and breast cancer incidence: a meta-analysis of observational studies

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Yujing He ◽  
Qinghua Tao ◽  
Feifei Zhou ◽  
Yuexiu Si ◽  
Rongrong Fu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Protective Effect ◽  
Dairy Products ◽  
Meta Analysis ◽  
Breast Cancer Incidence ◽  
Cochrane Library ◽  
Female Population ◽  
Fermented Dairy Products ◽  
Fermented Dairy ◽  
The Relationship

Abstract Background The effect of dairy products intake on breast cancer (BC) is highly controversial. This study aims to investigate the relationship between dairy intake and BC incidence. Methods A search was carried out in PubMed, EBSCO, Web of Science, and Cochrane Library databases before January 2021. The primary objective was the risk of BC and intake of dairy products were exposure variables. Results The meta-analysis comprised 36 articles with 1,019,232 participants. Total dairy products have a protective effect on female population (hazard ratio (HR) =0.95, 95% confidence interval (CI) =0.91–0.99, p = 0.019), especially for estrogen receptor-positive (ER+) (HR = 0.79, p = 0.002) and progesterone receptor-positive (PR+) BC (HR = 0.75, p = 0.027). For ER+/PR+ BC, there is a trend of protection, but it has not reached statistical significance (HR = 0.92, p = 0.075). Fermented dairy products can reduce BC risk in postmenopausal population (HR = 0.96, 95%CI = 0.93–0.99, p = 0.021), but have no protective effect on premenopausal population (HR = 0.98, 95%CI = 0.94–1.03, p = 0.52). Non-fermented dairy products have no significant effect on BC occurrence (p > 0.05). High-fat dairy products are harmful to women, without statistical difference (HR = 1.06, 95%CI = 1.00–1.13, p = 0.066). On the contrary, low-fat dairy products can protect the premenopausal population (HR = 0.94, 95%CI = 0.89–1.00, p = 0.048). Conclusion The intake of dairy products can overall reduce BC risk in the female population, but different dairy products have varying effects on different BC subtypes and menopausal status.

The relationship between time to initiation of adjuvant chemotherapy and survival in breast cancer: a systematic review and meta-analysis

2016 ◽  
Vol 160 (1) ◽  
pp. 17-28 ◽  
Author(s):  
Michael J. Raphael ◽  
James J. Biagi ◽  
Weidong Kong ◽  
Mihaela Mates ◽  
Christopher M. Booth ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Adjuvant Chemotherapy ◽  
Meta Analysis ◽  
Time To Initiation ◽  
The Relationship

The relationship between serum vitamin D levels and breast cancer prognosis: A meta-analysis.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 1521-1521
Author(s):  
April Ann Nicole Rose ◽  
Christine Elser ◽  
Pamela Jean Goodwin
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Vitamin D ◽  
Clinical Outcomes ◽  
Survival Data ◽  
Fixed Effects ◽  
Meta Analysis ◽  
Serum Vitamin ◽  
Vitamin D Levels ◽  
The Relationship

1521 Background: Vitamin D (VitD) is a circulating hormone known to regulate gene transcription in breast cancer (BC) cells. The association between VitD and BC risk has been extensively studied. Until recently, however, the role of VitD in BC progression and its association with clinical outcomes among BC patients was poorly understood. To assess these new developments, a systematic review and meta-analysis was performed. Methods: A systematic review and meta-analysis by searching MEDLINE (1982 – 2012), ASCO, and SABCS for abstracts (2009 – 2012), with the following keywords: “breast cancer” and “prognosis” or “survival”, and “vitamin D” or ”calcitriol.” Abstracts were scrutinized for reports correlating serum VitD levels with breast cancer clinical outcomes, including: disease-free survival (DFS) and overall survival (OS). Studies were included if serum VitD samples were taken shortly after diagnosis and survival data were reported. Meta-analyses were performed using an inverse-variance weighted fixed-effects model. Results: We identified 7 studies reporting correlative data between serum VitD levels and BC survival. These data included 4,885 patients evaluated for DFS and 3858 patients evaluated for OS. VitD-deficiency was defined as <30ng/mL, <20ng/mL, and <14ng/mL in 3, 3, and 1 studies, respectively, and was identified in an average of 48.1% of patients (range: 17.9-87.8%). VitD deficiency was associated with a pooled hazard ratio (HR) of 2.13 (CI: 1.64 - 2.78) and 1.76 (CI: 1.35 - 2.30) for DFS and OS, respectively. Conclusions: To our knowledge, this is the first report of a meta-analysis of the relationship between serum VitD and BC prognosis. The prevalence of VitD-deficiency varied widely across studies and may reflect differences in geographic location, race, and rates of supplementation across patient populations. These findings support the hypothesis that VitD-deficient breast cancer patients have poorer clinical outcomes than VitD sufficient patients; but do not establish whether this relationship is causative. Further studies are warranted to investigate the possible protective effects of VitD supplementation on survival among VitD-deficient BC patients.

Tumor infiltrating lymphocytes (TIL) to predict response to neoadjuvant chemotherapy in breast cancer: A systemic review and meta-analysis.

2014 ◽  
Vol 32 (26_suppl) ◽  
pp. 138-138 ◽  
Author(s):  
Yan Mao ◽  
Qing Qu ◽  
Yuzi Zhang ◽  
Junjun Liu ◽  
Kunwei Shen
Keyword(s):  
Breast Cancer ◽  
T Lymphocytes ◽  
Neoadjuvant Chemotherapy ◽  
Triple Negative ◽  
Meta Analysis ◽  
Tumor Infiltrating Lymphocytes ◽  
Pathological Response ◽  
Pre Treatment ◽  
Infiltrating Lymphocytes ◽  
The Relationship

138 Background: Whether tumor-infiltrating lymphocytes (TILs) predict response to neoadjuvant chemotherapy (NAC) remains elusive. Methods: A systematic review and meta-analysis was undertook to establish the relationship between TIL and pathological complete response (pCR) rate in NAC of breast cancer. A PubMed and Web of Science literature search was designed. Studies were included, in which the predictive significance of intratumoral and/or stromal TIL, and/or CD3+, CD4+, CD8+, and FOXP3+ lymphocytes were determined . Pooled ORs and publication bias was evaluated by STATA software. Results: A total of 13 published studies (including 3,555 patients) were eligible. In pooled analysis, higher number of TIL in pre-treatment biopsy was correlated with higher pCR rate of neoadjuvant chemotherapy, and odds ratio (OR) was 3.82 (95% confidence interval (CI), 3.10-4.70), no matter tested in intratumor (OR=3.32, 95% CI: 2.52-4.37), in stroma (OR=4.15,95% CI: 2.94-5.86), or in combined sites (OR=8.98, 95% CI: 3.79,21.30). Moreover, TIL predicts higher pCR rate in triple negative (OR=5.03,95% CI: 2.31-10.97) and HER2+ (OR=5.54,95% CI: 1.39-22.12) patients, but not in hormonal receptor (HR) +/HER2- patients (OR=2.57, 95% CI: 0.20-33.24). For TIL subsets, CD8+ T-lymphocytes predict better pathological response to NAC no matter in pre- (OR=3.36,95%CI: 1.15-9.85) or post-NAC (OR=4.71,95%CI: 1.29-17.27) tissue, while FOXP3+ T-lymphocytes have similar predictive roles only when tested after NAC (OR=4.26, 95%CI: 1.83-9.92).With limited study, the predictive role of CD3+ and CD4+T-lymphoctes were unclear, more perspective studies were needed in future to establish the relationship. Conclusions: High level of TIL in pre-treatment biopsy could be a good marker indicates better pathological response to NAC in triple-negative and HER2+ breast cancer patients. Different subsets have different predictive roles in the pCR rate to NAC. However, significant heterogeneity and an insufficient number of studies underscore the need for further prospective studies on subsets of T lymphocytes and different subtypes of breast cancer to increase the robustness of the analyses.

scholarly journals The prevalence of ataxia telangiectasia mutated (ATM) variants in patients with breast cancer patients: a systematic review and meta-analysis

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Masoumeh Moslemi ◽  
Maryam Vafaei ◽  
Pouria Khani ◽  
Marzieh Soheili ◽  
Reza Nedaeinia ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Meta Analysis ◽  
Breast Cancer Patients ◽  
Ataxia Telangiectasia Mutated ◽  
Brca Mutations ◽  
Cross Sectional ◽  
Pooled Prevalence ◽  
Atm Gene ◽  
The Relationship

AbstractBreast cancer is the most common cancer in women, and its high mortality has become one of the biggest health problems globally. Several studies have reported an association between breast cancer and ATM gene variants. This study aimed to demonstrate and analyze the relationship between ATM gene polymorphisms and breast cancer prevalence rate. A systematic literature review was undertaken using the following databases: Medline (PubMed), Web of sciences, Scopus, EMBASE, Cochrane, Ovid, and CINHAL to retrieve all cross-sectional studies between January 1990 and January 2020, which had reported the frequency of ATM variants in patients with breast cancer. A random-effects model was applied to calculate the pooled prevalence with a 95% confidence interval. The pooled prevalence of ATM variants in patients with breast cancer was 7% (95% CI: 5−8%). Also, the pooled estimate based on type of variants was 6% (95% CI: 4−8%; I square: 94%; P: 0.00) for total variants¸ 0% (95% CI: 0−1%; I square: 0%; P: 0.59) for deletion variants, 12% (95% CI: 7−18%; I square: 99%; P: 0.00) for substitution variants, and 2% (95% CI: 4−9%; I square: 67%; P: 0.08) for insertion variants. This meta-analysis showed that there is a significant relationship between ATM variants in breast cancer patients. Further studies are required to determine which of the variants of the ATM gene are associated with BRCA mutations.

Sign in / Sign up

Export Citation Format

Share Document